Breathe Well Live Well
|
AstraZeneca Buys Synairgen Asthma Drug For $7.25M
BioResearch Online (press release) AstraZeneca announced that it has signed into a global license agreement with Synairgen, a pharmaceutical company focused on respiratory disease, to buy SNG001, a novel immuno-modulatory therapy for viral-induced exacerbation in asthma. SNG001 is … |
View full post on asthma – Google News
|
AstraZeneca Buys Rights to Synairgen Asthma Compound
Genetic Engineering News SNG001 is an inhaled interferon beta (IFN-beta) for respiratory tract viral infections in patients with severe asthma. AstraZeneca said it plans early next years to launch a Phase IIa study of SNG001 in patients with severe asthma—a trial it said … |
View full post on asthma – Google News
|
AccentHealth buys Caervision's Asthma and Allergy waiting room television …
News-Medical.net AccentHealth, the leading patient education company at the Point-of-Care, announced today it has purchased the Asthma and Allergy waiting room television network of Caervision Corp. The new doctor office locations will become part of the AccentHealth … AccentHealth Grows Point-of-Care TV Network with Acquisition of Caervision's … |
View full post on asthma – Google News